abstract |
The present invention relates to glycolysis activating agents. The present invention also relates to the treatment or prevention of diseases or conditions, particularly diseases or conditions related to immunity. In particular, the present invention also relates to agents for use in the treatment or prevention of a disease or condition, said treatment or prevention being mediated by the circulation of endogenous regulatory T cells (Treg). |